News
-
-
-
COMMUNIQUÉ DE PRESSE
Laxxon Medical Announces Positive Pilot PK Study Results for Advanced Levodopa/Carbidopa Asset for Parkinson’s Disease, LMX.5
Laxxon Medical announces positive pilot PK study results for advanced Levodopa/Carbidopa asset LMX.5, showcasing improved bioavailability and sustained levodopa levels, revolutionizing Parkinson's disease treatment -
-
-
COMMUNIQUÉ DE PRESSE
Laxxon Medical Announces Positive Pilot PK Study Results (in Pigs) for Groundbreaking Oral GLP-1 Dosage Form
Laxxon Medical announces successful pilot PK study results for innovative oral GLP-1 weight loss tablet LXM.2, achieving 10-fold bioavailability increase. SPID®-Technology enhances drug delivery and patient compliance -
-
-
-